2020
Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population
Torabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache The Journal Of Head And Face Pain 2020, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.Peer-Reviewed Original ResearchConceptsAdvanced practice providersHigh-volume providersMedicare populationTreatment modalitiesMedicare patientsPractice providersSubstantial geographic variationMedicare Provider UtilizationProcedure volumeCPT codesPopular treatmentHigher mean numberNeurologistsCross-sectional dataProvider UtilizationMean numberPhysiciansSubstantial proportionChemodenervationReimbursement trendsTreatmentTotal beneficiariesProvidersTotalTotal numberEptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results
2015
Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
Schaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins 2015, 7: 2615-2628. PMID: 26184313, PMCID: PMC4516932, DOI: 10.3390/toxins7072615.Peer-Reviewed Original ResearchConceptsChronic migraineBotulinum toxin injection therapyLarge healthcare costsBotulinum toxin therapyTreatment of migraineCommon neurological disorderToxin therapyInjection therapyPathophysiological mechanismsMigraine pathophysiologyHealthcare costsMigraineNeurological disordersAnimal dataBotulinum neurotoxinTherapyTreatmentInjection techniqueCurrent understandingMedicationsPathophysiology